ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.692,65
1,28%
Brent Oil
82,765
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) Notícias

OCGN Ocugen Inc

1,34
0,02 (1,52%)
03 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Ocugen Inc OCGN NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,02 1,52% 1,34 20:59:32
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
1,36 1,32 1,42 1,33 1,32
mais cotações »

Notícias Recentes

Data Hora Fonte Título
03/05/202408:30GLOBEOcugen to Host Conference Call on Tuesday, May 14 at 8:30..
02/05/202408:15GLOBEOcugen Announces CSO to Present on Modifier Gene Therapy at..
29/04/202407:45GLOBEOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data..
26/04/202410:05GLOBEUPDATE -- Ocugen to Present on Modifier Gene Therapy..
26/04/202407:30GLOBEOcugen to Present on Modifier Gene Therapy Platform at..
19/04/202408:13GLOBEOcugen Announces Dosing Completion of Subjects with..
12/04/202408:30GLOBEOcugen to Participate in Fireside Chat at the Emerging..
10/04/202408:02GLOBEOcugen, Inc. Announces Positive Scientific Advice from the..
08/04/202407:30GLOBEOcugen, Inc. Announces U.S. FDA Clearance of IND Amendment..
05/04/202408:02GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
02/04/202409:00GLOBEOcugen Provides Business Update with Certain Financials for..
01/04/202419:08GLOBEOcugen Announces Positive Data and Safety Monitoring Board..
01/04/202418:43GLOBEOcugen to Host Conference Call on Tuesday, April 2 at 8:30..
18/03/202407:30GLOBEOcugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical..
13/03/202409:00GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
06/03/202409:30GLOBEOcugen to Present at Investing in Cures Summit
28/02/202410:00GLOBEOcugen Clinical Showcase Webcast Now Available
26/02/202410:30GLOBEOcugen Chairman and CEO to present at Abu Dhabi Family..
22/02/202418:05GLOBEOcugen, Inc. Announces Dosing Completion of Subjects with..
21/02/202418:05GLOBEOcugen to Present at 2024 BIO CEO & Investor Conference
14/02/202409:30GLOBEOcugen to Host Clinical Showcase in New York City..
31/01/202410:00GLOBEOcugen to Present at Pharma Market Research Conference
16/01/202409:30GLOBEOcugen, Inc. Announces Bob Smith Joins Business Advisory..
21/12/202308:30GLOBEOcugen Gains FDA Alignment on Key Aspects of OCU400—Modifier..
19/12/202309:30GLOBEOcugen Announces OCU400 Receives Regenerative Medicine..
13/12/202309:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
29/11/202309:30GLOBEOcugen CEO to Present at NobleCon19 – Noble Capital Markets’..
10/11/202309:30GLOBEOcugen, Inc. Announces First Patient Dosed in Phase 1/2..
09/11/202308:30GLOBEOcugen Provides Business Update with Third Quarter 2023..
07/11/202309:45GLOBEOcugen CSO to Participate in 4th Annual Dry AMD Therapeutic..
02/11/202308:30GLOBEOcugen to Host Conference Call on Thursday, November 9 at..
10/10/202307:30GLOBEOcugen Mucosal Vaccine Candidate OCU500 Selected by..
04/10/202308:00GLOBEOcugen to Present at the 2023 Cell & Gene Meeting on the..
29/09/202308:30GLOBEOcugen CSO to Participate in 4th Annual Gene Therapy for..
27/09/202320:30GLOBEOcugen to Participate in Fireside Chat at Chardan’s 7th..
21/09/202308:30GLOBEOcugen, Inc. Announces Connie Collingsworth Joins Business..
20/09/202309:00GLOBEOcugen to Participate in Panel at Cantor Fitzgerald Global..
13/09/202309:15GLOBEOcugen Announces Positive Clinical Study Update from the..
12/09/202320:30GLOBEOcugen to Host Virtual Investor & Analyst Event on September..
21/08/202317:32GLOBEOcugen Provides Business Update with Second Quarter 2023..
18/08/202317:39GLOBEOcugen to Host Conference Call on Tuesday, August 22 at 8:30..
30/06/202309:00GLOBEOcugen CEO & CSO to Present at 41st Annual AAPI Convention..
09/06/202317:05GLOBEOcugen, Inc. Announces Adjournment of Annual Meeting of..
05/06/202308:02GLOBEOcugen, Inc. Announces Business Advisory Board
24/05/202309:36GLOBEOcugen, Inc. Announces Pricing of $16.5 Million Public..
23/05/202317:01GLOBEOcugen, Inc. Announces Proposed Public Offering of Common..
23/05/202309:00GLOBEOcugen to Present at BIO International Convention 2023
05/05/202308:00GLOBEOcugen Provides Business Update with First Quarter 2023..

Seu Histórico Recente

NASDAQ
OCGN
Ocugen
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados